 | |  | |  | |  | |  | |  | |  | |  |
| IJCEP Copyright © 2007-All rights reserved. |
| International Journal of Clinical and Experimental Pathology |
Int J Clin Exp Pathol 1(2):124-133;2008
Original Article
Prognostic Significance of Flow Cytometric Immunophenotyping in Acute Myeloid
Leukemia
Brian A. Webber, Melissa M. Cushing and Shiyong Li
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
Received 2 Aug 2007; accepted and available online 1 January 2008
Abstract: The prognostic significance of flow cytometric immunophenotyping (FCI) in acute myeloid leukemia (AML) has been
controversial. In this study, we re-investigated the possible role of FCI in the prediction of AML relapse following standard chemotherapy. A
total of 209 AML cases with follow-up information were analyzed. Among those, 78 cases were in remission (M:F=44/34; mean age of
48.9 years) and 131 had relapse (M:F=71/60; mean age of 51.3 years). The expression of CD34, HLA-DR or a combination of both was
significantly different between the remission and relapse groups for all AML as well as AML without t(15;17). None of the pammyeloid
markers or their combinations analyzed was found to correlate with treatment outcomes. Complex cytogenetic abnormalities were more
likely associated with relapse group than with remission group, but were not statistically significant after excluding AML with t(15;17). In
conclusion, FCI is useful in predicting treatment outcome and disease relapse in AML. (IJCEP708010).
Key Words: Flow cytometric immunophenotyping, acute myeloid leukemia, acute promyelocytic leukemia, chromosome translocation,
cytogenetics, prognosis
Full Text PDF
Address all correspondences to: Shiyong Li, MD, PhD, Department of Pathology and Laboratory Medicine, Emory University Hospital
F143D, 1364 Clifton Road NE, Atlanta, GA 30322. Tel: 404-712-5456; Fax: 404-712-4140; Email: sli2@emory.edu
Original Article
Prognostic Significance of Flow Cytometric Immunophenotyping in Acute Myeloid
Leukemia
Brian A. Webber, Melissa M. Cushing and Shiyong Li
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
Received 2 Aug 2007; accepted and available online 1 January 2008
Abstract: The prognostic significance of flow cytometric immunophenotyping (FCI) in acute myeloid leukemia (AML) has been
controversial. In this study, we re-investigated the possible role of FCI in the prediction of AML relapse following standard chemotherapy. A
total of 209 AML cases with follow-up information were analyzed. Among those, 78 cases were in remission (M:F=44/34; mean age of
48.9 years) and 131 had relapse (M:F=71/60; mean age of 51.3 years). The expression of CD34, HLA-DR or a combination of both was
significantly different between the remission and relapse groups for all AML as well as AML without t(15;17). None of the pammyeloid
markers or their combinations analyzed was found to correlate with treatment outcomes. Complex cytogenetic abnormalities were more
likely associated with relapse group than with remission group, but were not statistically significant after excluding AML with t(15;17). In
conclusion, FCI is useful in predicting treatment outcome and disease relapse in AML. (IJCEP708010).
Key Words: Flow cytometric immunophenotyping, acute myeloid leukemia, acute promyelocytic leukemia, chromosome translocation,
cytogenetics, prognosis
Full Text PDF
Address all correspondences to: Shiyong Li, MD, PhD, Department of Pathology and Laboratory Medicine, Emory University Hospital
F143D, 1364 Clifton Road NE, Atlanta, GA 30322. Tel: 404-712-5456; Fax: 404-712-4140; Email: sli2@emory.edu